Affinity DataKi: 0.0450nMAssay Description:Inhibition of rat squalene synthaseMore data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
National Institute of Environmental Health Sciences
Curated by ChEMBL
National Institute of Environmental Health Sciences
Curated by ChEMBL
Affinity DataKi: 0.120nMAssay Description:Compound was tested for its binding affinity against opioid receptor delta using [3H]-DPDPE as radioligand.More data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
National Institute of Environmental Health Sciences
Curated by ChEMBL
National Institute of Environmental Health Sciences
Curated by ChEMBL
Affinity DataKi: 0.120nMAssay Description:Binding affinity against Opioid receptor delta 1 in P2 membrane preparation of rat brain by [3H]DADLE displacement.More data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
National Institute of Environmental Health Sciences
Curated by ChEMBL
National Institute of Environmental Health Sciences
Curated by ChEMBL
Affinity DataKi: 0.200nMAssay Description:Binding affinity against Opioid receptor delta 1 in P2 membrane preparation of rat brain by [3H]DADLE displacement.More data for this Ligand-Target Pair
Affinity DataKi: 0.200nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
National Institute of Environmental Health Sciences
Curated by ChEMBL
National Institute of Environmental Health Sciences
Curated by ChEMBL
Affinity DataKi: 0.210nMAssay Description:Inhibition of [3H]-DADLE binding to opioid receptor delta in P2 membrane preparation of rat brainMore data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
National Institute of Environmental Health Sciences
Curated by ChEMBL
National Institute of Environmental Health Sciences
Curated by ChEMBL
Affinity DataKi: 0.220nMAssay Description:Binding affinity against Opioid receptor delta 1 in P2 membrane preparation of rat brain by [3H]DADLE displacement.More data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
National Institute of Environmental Health Sciences
Curated by ChEMBL
National Institute of Environmental Health Sciences
Curated by ChEMBL
Affinity DataKi: 0.220nMAssay Description:Binding affinity against Opioid receptor delta 1 in P2 membrane preparation of rat brain by [3H]DADLE displacement.More data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
National Institute of Environmental Health Sciences
Curated by ChEMBL
National Institute of Environmental Health Sciences
Curated by ChEMBL
Affinity DataKi: 0.260nMAssay Description:Binding affinity against Opioid receptor delta 1 in P2 membrane preparation of rat brain by [3H]DADLE displacement.More data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
National Institute of Environmental Health Sciences
Curated by ChEMBL
National Institute of Environmental Health Sciences
Curated by ChEMBL
Affinity DataKi: 0.310nMAssay Description:Inhibition of [3H]-DADLE binding to opioid receptor delta in P2 membrane preparation of rat brainMore data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
National Institute of Environmental Health Sciences
Curated by ChEMBL
National Institute of Environmental Health Sciences
Curated by ChEMBL
Affinity DataKi: 0.360nMAssay Description:Compound was tested for its binding affinity against opioid receptor delta using [3H]-DPDPE as radioligand.More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.400nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.400nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.400nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.400nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
National Institute of Environmental Health Sciences
Curated by ChEMBL
National Institute of Environmental Health Sciences
Curated by ChEMBL
Affinity DataKi: 0.410nMAssay Description:Inhibition of [3H]-DPDPE binding to Opioid receptor delta 1More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.420nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
National Institute of Environmental Health Sciences
Curated by ChEMBL
National Institute of Environmental Health Sciences
Curated by ChEMBL
Affinity DataKi: 0.450nMAssay Description:Compound was tested for its binding affinity against opioid receptor delta using [3H]-DPDPE as radioligand.More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.450nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.490nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.5nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.510nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.520nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.530nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
National Institute of Environmental Health Sciences
Curated by ChEMBL
National Institute of Environmental Health Sciences
Curated by ChEMBL
Affinity DataKi: 0.540nMAssay Description:Inhibition of [3H]-DPDPE binding to Opioid receptor delta 1More data for this Ligand-Target Pair
Affinity DataKi: 0.540nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.560nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.560nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.600nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.600nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.620nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.620nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.620nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.630nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.630nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.640nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.650nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Rattus norvegicus (rat))
National Institute of Environmental Health Sciences
Curated by ChEMBL
National Institute of Environmental Health Sciences
Curated by ChEMBL
Affinity DataKi: 0.650nMAssay Description:Inhibition of [3H]-DADLE binding to opioid receptor delta in P2 membrane preparation of rat brainMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Rattus norvegicus (rat))
National Institute Of Environmental Health Sciences
Curated by ChEMBL
National Institute Of Environmental Health Sciences
Curated by ChEMBL
Affinity DataKi: 0.660nMAssay Description:Binding affinity against Opioid receptor mu 1 in P2 membrane preparation of rat brain by [3H]DAGO displacement.More data for this Ligand-Target Pair
Affinity DataKi: 0.680nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
Affinity DataKi: 0.680nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.690nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetMu-type opioid receptor(Rattus norvegicus (rat))
National Institute Of Environmental Health Sciences
Curated by ChEMBL
National Institute Of Environmental Health Sciences
Curated by ChEMBL
Affinity DataKi: 0.700nMAssay Description:Binding affinity against Opioid receptor mu 1 in P2 membrane preparation of rat brain by [3H]DAGO displacement.More data for this Ligand-Target Pair
Affinity DataKi: 0.770nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.780nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.790nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.790nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.800nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.800nMAssay Description:In a typical experiment the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experi...More data for this Ligand-Target Pair